Investigational drug · Phase 3
LYR-210
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis).
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "LYR-210"
First trial start
2022
May 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LYR-210", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Sinusitis
- Chronic Rhinosinusitis (Diagnosis)
Largest trials
Live from ClinicalTrials.gov: studies naming "LYR-210" as an intervention, largest first.
- Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in AdultsPivotal-lookingCompleted
Lyra TherapeuticsIndustry
NCT05219968 · 196 participants · Start Jan 27, 2022 · Primary completion Mar 4, 2024
Drug: LYR-210; Sham procedure control · For: Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)
Sites: Birmingham, Alabama; Escondido, California; La Mesa, California · 55 sites in all
- Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)Pivotal-lookingCompleted
Lyra TherapeuticsIndustry
NCT05295459 · 182 participants · Start May 13, 2022 · Primary completion Apr 2, 2025
Drug: LYR-210; Sham procedure control · For: Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)
Sites: Tucson, Arizona; Arcadia, California; Los Angeles, California · 57 sites in all
Lyra TherapeuticsIndustry
NCT04041609 · 71 participants · Start May 9, 2019 · Primary completion Mar 25, 2020
Drug: LYR-210 · For: Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)
Sites: Brisbane, Australia; Clayton, Australia; Hornsby, Australia · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Impact of long-acting implantable LYR-210 corticosteroid matrices on quality of life of patients with chronic rhinosinusitis in the LANTERN study.
Rimmer J, Cervin A, Wrobel A, et al. · Int Forum Allergy Rhinol 2023
- Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis.
Ow RA, Shotts S, Kakarlapudi V, et al. · Am J Rhinol Allergy 2022
- Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study.
Cervin A, Rimmer J, Wrobel A, et al. · Int Forum Allergy Rhinol 2022
- Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis.
Douglas RG, Psaltis AJ, Rimmer J, et al. · Int Forum Allergy Rhinol 2019
Also in development for Chronic Sinusitis
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.